Genetic variants of microsomal triglyceride transfer protein (mttp) are associated with metabolic syndrome in schizophrenic patients treated with atypical antipsychotics

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 313-318

  Liou, Ying Jay ^a,b   Tsai, Shih Jen ^a,b   Wang, Ying Chieh ^c   Bai, Ya Mei ^a,b   Hong, Chen Jee ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

Author keywords

atypical antipsychotic; metabolic syndrome; microsomal triglyceride transfer protein (MTTP); single nucleotide polymorphisms

Indexed keywords

CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; OLANZAPINE; RISPERIDONE;

ADULT; ALCOHOL CONSUMPTION; ALLELE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WAIST CIRCUMFERENCE;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CARRIER PROTEINS; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SCHIZOPHRENIA; TIME FACTORS;

EID: 84877584091     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31828bf288     Document Type: Article

References (30)

1. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006; 83: 87-93.
2. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005; 80: 19-32.
3. De Hert M, Schreurs V, Vancampfort D, et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009; 8: 15-22.
4. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009; 119: 4-14.
5. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007; 68(suppl 4): 8-13.
6. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008; 101: 295-303.
7. Gautam S, Meena PS. Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics. Indian J Psychiatry. 2011; 53: 128-133.
8. Hasnain M, Fredrickson SK, Vieweg WV, et al. Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diab Rep. 2010; 10: 209-216.
9. Mulder H, Franke B, van der-Beek van der AA, et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. J Clin Psychopharmacol. 2007; 27: 338-343.
10. Mulder H, Cohen D, Scheffer H, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol. 2009; 29: 16-20.
11. Bai YM, Chen TT, Liou YJ, et al. Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. Schizophr Res. 2011; 125: 179-186.
12. Liou YJ, Bai YM, Lin E, et al. Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics. Pharmacogenomics J. 2012; 12(1): 54-61.
13. Ellingrod VL, Miller del D, Taylor SF, et al. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res. 2008; 98: 47-54.
14. van Winkel R, Rutten BP, Peerbooms O, et al. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res. 2010; 121: 193-198.
15. Sharp D, Ricci B, Kienzle B, et al. Human microsomal triglyceride transfer protein large subunit gene structure. Biochemistry. 1994; 33: 9057-9061.
16. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997; 1345: 136-150.
17. Blasiole DA, Davis RA, Attie AD. The physiological and molecular regulation of lipoprotein assembly and secretion. Mol Biosyst. 2007; 3: 608-619.
18. Karpe F, Lundahl B, Ehrenborg E, et al. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler Thromb Vasc Biol. 1998; 18: 756-761.
19. Ledmyr H, Karpe F, Lundahl B, et al. Variants of the microsomal triglyceride transfer protein gene are associated with plasma cholesterol levels and body mass index. J Lipid Res. 2002; 43: 51-58.
20. Yamada Y, Ando F, Shimokata H. Association of a microsomal triglyceride transfer protein gene polymorphism with blood pressure in Japanese women. Int J Mol Med. 2006; 17: 83-88.
21. Garc?a-Garc?a AB, Gonzalez C, Real JT, et al. Influence of microsomal triglyceride transfer protein promoter polymorphism-493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia. Pharmacogenet Genomics. 2005; 15: 211-218.
22. Bohme M, Grallert H, Fischer A, et al. MTTP variants and body mass index, waist circumference and serum cholesterol level: association analyses in 7582 participants of the KORA study cohort. Mol Genet Metab. 2008; 95: 229-232.
23. Hong CJ, Liou YJ, Bai YM, et al. Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenet Genomics. 2010; 20: 359-366.
24. Ledmyr H, Ottosson L, Sunnerhagen M, et al. The Ile128Thr polymorphism influences stability and ligand binding properties of the microsomal triglyceride transfer protein. J Lipid Res. 2006; 47: 1378-1385.
25. Juo SH, Han Z, Smith JD, et al. Common polymorphism in promoter of microsomal triglyceride transfer protein gene influences cholesterol, ApoB, and triglyceride levels in young African American men: results from the coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb Vasc Biol. 2000; 20: 1316-1322.
26. Couture P, Otvos JD, Cupples LA, et al. Absence of association between genetic variation in the promoter of the microsomal triglyceride transfer protein gene and plasma lipoproteins in the Framingham Offspring Study. Atherosclerosis. 2000; 148: 337-343.
27. Zak A, Jachymova M, Tvrzicka E, et al. The influence of polymorphism of-493G/T MTP gene promoter and metabolic syndrome on lipids, fatty acids and oxidative stress. J Nutr Biochem. 2008; 19: 634-641.
28. De Luca V, Mueller DJ, de Bartolomeis A, et al. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol. 2007; 10: 697-704.
29. Vimaleswaran KS, Zhao JH, Wainwright NW, et al. Association between serotonin 5-HT-2C receptor gene (HTR2C) polymorphisms and obesity-and mental health-related phenotypes in a large population-based cohort. Int J Obes (Lond). 2010; 34: 1028-1033.
30. Wierzbicki AS, Hardman T, Prince WT. Future challenges for microsomal transport protein inhibitors. Curr Vasc Pharmacol. 2009; 7: 277-286.